
  
    
      
        
        The_DT immune_JJ system_NN has_VBZ a_DT remarkable_JJ capacity_NN for_IN fending_VBG off_RP infectious_JJ diseases_NNS ,_, and_CC it_PRP
        has_VBZ become_VBN clear_JJ that_IN these_DT same_JJ defenses_NNS can_MD recognize_VB and_CC destroy_VB cancer_NN cells_NNS ._. In_IN fact_NN ,_,
        they_PRP do_VBP so_RB on_IN an_DT ongoing_JJ basis_NN ,_, and_CC cancer_NN develops_VBZ only_RB when_WRB immune_JJ surveillance_NN breaks_NNS
        down_RB ._. Many_JJ patients_NNS with_IN established_VBN tumors_NNS also_RB mount_VBP an_DT immune_JJ response_NN against_IN some_DT
        antigens_NNS that_WDT are_VBP specific_JJ to_TO ,_, or_CC enriched_JJ in_IN ,_, the_DT tumor_NN ._. This_DT response_NN ,_, however_RB ,_, is_VBZ rarely_RB
        effective_JJ against_IN the_DT disease_NN ._.
        The_DT idea_NN of_IN enlisting_VBG the_DT immune_JJ system_NN to_TO fight_VB cancer_NN has_VBZ been_VBN around_IN for_IN a_DT long_JJ time_NN ,_,
        and_CC has_VBZ led_VBN to_TO the_DT development_NN of_IN various_JJ cancer_NN vaccines_NNS designed_VBN to_TO alert_VB the_DT immune_JJ
        system_NN to_TO the_DT presence_NN of_IN a_DT tumor_NN and_CC to_TO induce_VB a_DT response_NN that_IN ,_, selectively_RB and_CC potently_RB ,_,
        will_MD eliminate_VB tumor_NN cells_NNS ._. Vaccines_NNP include_VBP whole_JJ tumor_NN extracts_NNS or_CC specific_JJ proteins_NNS and_CC
        peptides_NNS that_WDT are_VBP selectively_RB expressed_VBN or_CC enriched_JJ in_IN tumors_NNS ,_, by_IN themselves_PRP or_CC with_IN a_DT
        variety_NN of_IN adjuvants_NNS ._.
        There_EX have_VBP been_VBN some_DT spectacular_JJ successes_NNS ,_, in_IN particular_JJ with_IN immune_JJ therapy_NN to_TO
        malignant_JJ melanoma_NN ,_, a_DT tumor_NN type_NN that_WDT seems_VBZ naturally_RB to_TO be_VB more_RBR immunogenic_JJ than_IN others_NNS ._.
        However_RB ,_, even_RB in_IN melanoma_NN ,_, success_NN is_VBZ usually_RB restricted_VBN to_TO a_DT fraction_NN of_IN the_DT patients_NNS ,_,
        with_IN no_DT obvious_JJ explanation_NN of_IN why_WRB the_DT strategy_NN works_VBZ for_IN a_DT particular_JJ patient_NN and_CC fails_VBZ in_IN
        most_JJS others_NNS ._. The_DT emphasis_NN has_VBZ consequently_RB shifted_VBN from_IN clinical_JJ outcomes_NNS to_TO monitoring_VBG a_DT
        patient_NN 's_POS immune_JJ response_NN ._. What_WP type_NN of_IN response_NN is_VBZ necessary_JJ and_CC sufficient_JJ to_TO eliminate_VB
        tumor_NN cells_NNS is_VBZ still_RB unclear_JJ ,_, but_CC the_DT hope_NN is_VBZ that_DT understanding_VBG the_DT immune_JJ response_NN in_IN
        patients_NNS that_WDT show_NN clinical_JJ benefit_NN will_MD answer_VB that_DT question_NN ._.
        Peter_NNP Lee_NNP and_CC colleagues_NNS used_VBD state-of-the_JJ art_NN technology_NN to_TO dissect_NN the_DT endogenous_JJ
        immune_JJ response_NN to_TO vaccination_NN with_IN heteroclitic_JJ melanoma_NN peptides_NNS ,_, i_NNP ._. e_SYM ._. ,_,
        melanoma-associated_JJ peptides_NNS that_WDT have_VBP been_VBN engineered_VBN to_TO elicit_NN a_DT stronger_JJR immune_JJ
        response_NN ._. They_PRP focused_VBD on_IN cytotoxic_JJ T_NN lymphocytes_NNS (_( CTLs_NNP )_) ,_, and_CC compared_VBD CTL_NNP clones_NNS from_IN four_CD
        melanoma_NN patients_NNS who_WP had_VBD vaccine-induced_JJ T_NN cell_NN responses_NNS and_CC two_CD melanoma_NN patients_NNS with_IN
        spontaneous_JJ anti-tumor_JJ T_NN cell_NN responses_NNS ._. The_DT researchers_NNS analyzed_VBD several_JJ hundred_CD CTL_NNP
        clones_NNS (_( to_TO get_VB a_DT sense_NN for_IN the_DT complexity_NN of_IN the_DT responses_NNS in_IN individual_JJ patients_NNS )_) for_IN T_NN
        cell_NN receptor_NN variable_JJ chain_NN beta_NN expression_NN ,_, recognition_NN efficiency_NN ,_, and_CC ability_NN to_TO lyse_NN
        target_NN melanoma_NN cells_NNS ._. Most_JJS T_NN cells_NNS isolated_VBN from_IN vaccinated_JJ patients_NNS were_VBD poor_JJ at_IN tumor_NN
        cell_NN lysis_NNS compared_VBN with_IN T_NN cells_NNS from_IN endogenous_JJ responses_NNS to_TO cancer_NN ._.
        The_DT authors_NNS suggest_VBP that_IN the_DT high_JJ doses_NNS of_IN peptides_NNS administered_VBN in_IN vaccinations_NNS and_CC the_DT
        increased_VBN binding_JJ capacity_NN of_IN heteroclitic_JJ peptides_NNS to_TO major_JJ histocompatibility_NN complex_JJ
        molecules—the_NN very_RB quality_NN that_WDT makes_VBZ them_PRP more_JJR immunogenic—induce_NN many_JJ T_NN cells_NNS with_IN low_JJ
        recognition_NN efficiency_NN for_IN the_DT native_JJ peptides_NNS they_PRP encounter_VB on_IN the_DT tumor_NN cells_NNS ._. Their_PRP$
        findings_NNS also_RB bring_VBP into_IN question_NN the_DT ability_NN to_TO deduce_NN the_DT recognition_NN efficiency_NN and_CC
        tumor_NN reactivity_NN of_IN T_NN cell_NN responses_NNS from_IN ELISPOT_NNP and_CC tetramer_NN staining_VBG assays—the_NN two_CD
        standard_JJ measures_NNS of_IN T_NN cell_NN responses_NNS to_TO vaccines—which_NN has_VBZ implications_NNS for_IN rational_JJ
        vaccine_NN design_NN in_IN general_NN ._.
      
    
  
